Research programme: B-RAF kinase inhibitors - Aravive Biologics

Drug Profile

Research programme: B-RAF kinase inhibitors - Aravive Biologics

Alternative Names: B-series

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ruga Corporation; Selexagen Therapeutics
  • Developer Aravive Biologics
  • Class
  • Mechanism of Action Mitogen-activated protein kinase inhibitors; Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 17 May 2012 Ruga Corporation acquires a B-RAF kinase programme from Selexagen Therapeutics
  • 17 May 2012 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top